Vandetanib Advantages in Medullary Thyroid Cancer

Video

Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Related Content
US FDA

Petosemtamab Receives FDA Breakthrough Therapy Designation in Pretreated HNSCC

May 13th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Kevin Harrington, BSc, MBBS, MRCP, FRCR, FRCP, PhD, DIC

Setanaxib Plus Pembrolizumab Improves Survival in Recurrent/Metastatic HNSCC

May 7th 2024
Article
Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

September 2nd 2021
Podcast
stock.adobe.com

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC

April 24th 2024
Article
Jameel Muzaffar, MD

Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC

April 21st 2024
Article